Clinical trial
A Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab With Darbepoetin Alfa in Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Who Have Failed Erythropoietin Stimulating Agents (ESA)
NCT04798339 is registered in ClinicalTrials.gov with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab With Darbepoetin Alfa in Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Who Have Failed Erythropoietin Stimulating Agents (ESA)
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- March 30, 2021
- Completion date
- July 31, 2026
- Enrollment
- 13 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.